Press Releases

RENO, Nev. , Dec. 14, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps").  Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later than

Expects to File a Certificate of Dissolution on January 4, 2021 Trading in PDL's Common Stock on Nasdaq to be Suspended Prior to Market Opening on December 31, 2020 INCLINE VILLAGE, Nev. , Dec. 8, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that

- Consummated critical monetization transactions during third quarter, including the sale of its Noden pharmaceutical business and of a basket of royalties to SWK Holdings. Also entered into a settlement agreement with Wellstat. Subsequently completed the spin-off of its medical device company,

Conference Call to Wednesday, November 11 at 4:30 p.m. Eastern Time INCLINE VILLAGE, Nev. , Nov. 6, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference

INCLINE VILLAGE, Nev. , Oct. 29, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its third quarter 2020 financial results for the period ended September 30, 2020 , on Monday, November 9, 2020 after market close.

INCLINE VILLAGE, Nev. , Oct. 2, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its femtosecond laser system business, LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR").

Declares Record Date of September 22, 2020 and Expected Share Distribution Date of October 1, 2020   Conference call with slide presentation today beginning at 4:30 p.m. Eastern time INCLINE VILLAGE, Nev. , Sept. 10, 2020 /PRNewswire/ --  PDL BioPharma, Inc.

INCLINE VILLAGE, Nev. , Sept. 9, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively " Noden ") to Stanley Capital .

INCLINE VILLAGE, Nev. , Aug. 31, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella ® , Zalviso ® , and Coflex ® (collectively the "Royalties") to SWK

INCLINE VILLAGE, Nev. , Aug. 28, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes" and together with the 2021 Notes, the

INCLINE VILLAGE, Nev. , Aug. 26, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that its majority owned medical device subsidiary, LENSAR, Inc. (" LENSAR "), has filed a registration statement on Form 10 with the Securities and Exchange Commission

INCLINE VILLAGE, Nev. , Aug. 12, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a settlement agreement (the "Settlement Agreement") with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC ) (" Wellstat

- Accomplished Important Asset Monetization Milestones with the Distribution of Evofem Biosciences Shares to PDL Stockholders and the Anticipated Sale of Noden to Stanley Capital   - Announced the Filing of a Form 10 with SEC for Potential Spin-off of LENSAR   - Continues to Seek Potential

INCLINE VILLAGE, Nev. , July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period ended June 30, 2020 , on Thursday, August 6, 2020 , after market close.

INCLINE VILLAGE, Nev. , July 30, 2020 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively " Noden ")